Pharmacological agents such as ergothioneine acid reduce the SSG of NF-κB-dependent Wnt5a-sFlt1, improving post-MI outcomes by preserving GRX1 activity and myocardial integrity (84). Here, GLRX is linked to myocardial infarction.